HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1

被引:15
|
作者
Quesnel-Vallieres, Mathieu [1 ,4 ]
Lemay, Mireille [2 ,5 ]
Lapointe, Normand [2 ,5 ]
Martin, Steven R. [3 ,5 ]
Soudeyns, Hugo [1 ,4 ,5 ]
机构
[1] CHU St Justine, Ctr Rech, Unite Immunopathol Virale, Montreal, PQ H3T 1C5, Canada
[2] CHU St Justine, Ctr Rech, Ctr Maternal & Infantile SIDA, Montreal, PQ H3T 1C5, Canada
[3] CHU St Justine, Ctr Rech, Serv Gastroenterol & Nutr, Montreal, PQ H3T 1C5, Canada
[4] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada
[5] Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ H3C 3J7, Canada
关键词
Hepatitis C virus; Coinfection; Pediatrics; Mother-to-child transmission; Interferon; Ribavirin;
D O I
10.1016/j.jcv.2008.06.019
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Two children who acquired hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infection by mother-to-child transmission were monitored during interferon alfa-2b and ribavirin treatment. In Patient C1, CD4(+) T cell counts were within normal range and HIV-1 viral load was undetectable. HCV viral load declined slightly following treatment initiation while novel variants rapidly emerged, indicative of quasispecies diversification. In Patient C2, CD4(+) T cell counts were low and HIV-1 replication was not fully controlled by antiretroviral therapy. HCV viral load rose during treatment and a striking conservation of the variant spectrum was observed. In both cases, there was no decline in quasispecies complexity following treatment initiation and sustained virological response was not achieved. These results suggest that reduction in quasispecies complexity, which is observed in adult responders following interferon treatment, may be mechanistically unrelated with evolution of the variant profile and/or selective pressure exerted on HCV. (C) 2008 Elsevier B.V. All rights reserved
引用
收藏
页码:236 / 240
页数:5
相关论文
共 50 条
  • [1] Pegylated interferon alfa-2b and ribavirin in HIV/HCV-coinfected patients.
    Myers, RP
    Benhamou, Y
    Bochet, M
    Mehri, D
    Di Martino, V
    Valantin, MA
    Katlama, C
    Bricaire, F
    Poynard, T
    HEPATOLOGY, 2002, 36 (04) : 575A - 575A
  • [2] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients
    Laguno, M
    Murillas, J
    Blanco, JL
    Martínez, E
    Miquel, R
    Sánchez-Tapias, JM
    Bargallo, X
    García-Criado, A
    de Lazzari, E
    Larrousse, M
    León, A
    Loncá, M
    Milinkovic, A
    Gatell, JM
    Mallolas, J
    AIDS, 2004, 18 (13) : F27 - F36
  • [3] Chorea during treatment with pegylated interferon and ribavirin in HIV-HCV coinfected patient
    Luisa Montes, Maria
    Maria Fraile, Jose
    Julian Gonzalez, Juan
    Ramon Arribas, Jose
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2009, 27 (01): : 60 - 61
  • [4] Peginterferon alfa-2b plus ribavirin versus interferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients
    Crespo, M
    Sauleda, S
    Esteban, JI
    Juarez, A
    Buti, M
    Pahissa, A
    Esteban, R
    Guardia, J
    HEPATOLOGY, 2005, 42 (04) : 701A - 702A
  • [5] Impact of Interferon-Ribavirin Treatment on Hepatitis C Virus (HCV) Protease Quasispecies Diversity in HIV- and HCV-Coinfected Patients
    Chary, Aarthi
    Winters, Mark A.
    Kottilil, Shyam
    Murphy, Alison A.
    Polis, Michael A.
    Holodniy, Mark
    JOURNAL OF INFECTIOUS DISEASES, 2010, 202 (06): : 889 - 893
  • [6] IMPROVEMENT OF ADIPOKINES IN HCV ERADICATED PATIENT TREATED WITH PEGYLATED INTERFERON ALFA-2B AND RIBAVIRIN
    Kaneko, Fumihiko
    Yokomori, Hiroaki
    Kumagai, Naoki
    Toda, Kyoko
    Tsunematsu, Satoshi
    Wakabayashi, Kanji
    Tsuchimoto, Kanji
    Saito, Hidetsugu
    Hibi, Toshifumi
    HEPATOLOGY, 2010, 52 (04) : 808A - 808A
  • [7] HCV clearance from saliva of HIV-HCV-coinfected patients on treatment with interferon plus ribavirin
    Feijoo, J.
    Eirea, M.
    Limeres, J.
    Abeleira, M.
    Ramos, I.
    Ocampo, A.
    Diz, P.
    ORAL DISEASES, 2014, 20 (03) : 313 - 318
  • [8] Blood transaminase elevation with pegylated interferon alfa 2b plus ribavirin in an HIV/HCV coinfected haemophilic patient
    Guitton, E.
    Barange, K.
    Bagheri, H.
    Claeyssens, S.
    Bonnet, E.
    Massip, P.
    Montastruc, J. L.
    Vinel, J. P.
    INFECTION, 2006, 34 (03) : 183 - 185
  • [9] Blood Transaminase Elevation with Pegylated Interferon Alfa 2b Plus Ribavirin in an HIV/HCV Coinfected Haemophilic Patient
    E. Guitton
    K. Barange
    H. Bagheri
    J. L. Montastruc
    J. P. Vinel
    S. Claeyssens
    E. Bonnet
    P. Massip
    Infection, 2006, 34 : 183 - 185
  • [10] Treatment with Peg-Interferon alfa-2b (PEG-IFN) plus ribavirin compared to interferon alfa-2b (INF alfa-2b)plus ribavirin on subjects with chronic hepatitis C infected with HCV genotype 4.
    Esmat, G
    Abouzied, AM
    Abdel-Aziz, F
    Mohamed, MK
    Abdel-Hamid, M
    El Raziky, MS
    Ismail, SA
    Zalata, KR
    Mikhail, NN
    Fix, A
    Strickland, T
    Sjogren, MH
    HEPATOLOGY, 2002, 36 (04) : 364A - 364A